Lisik Daniil, Zou Ding
Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 424, Gothenburg 405 30, Sweden.
Center for Sleep and Vigilance Disorders, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Medicinaregatan 8B, Box 421, Gothenburg 405 30, Sweden.
Sleep Med Clin. 2025 Mar;20(1):103-114. doi: 10.1016/j.jsmc.2024.10.002. Epub 2024 Dec 10.
Obstructive sleep apnea (OSA) is a heterogeneous condition characterized by diverse endotypic traits and clinical phenotypes. A recent randomized controlled trial evaluating a glucagon-like peptide-1 receptor agonist showed promising results, potentially making it the first on-label drug treatment for OSA. Phase II/III clinical trials investigating combinations of noradrenergic and antimuscarinic agents, as well as carbonic anhydrase inhibitors, are ongoing. Future drug treatments for OSA, either as monotherapy or combined with other treatment modalities, will be personalized and based on treatable traits to address underlying mechanisms, comorbid conditions, and patient-reported outcome measures.
阻塞性睡眠呼吸暂停（OSA）是一种异质性疾病，具有多种内型特征和临床表型。最近一项评估胰高血糖素样肽-1受体激动剂的随机对照试验显示出了有前景的结果，这可能使其成为首个获批用于治疗OSA的药物。正在进行的II/III期临床试验研究了去甲肾上腺素能和抗毒蕈碱药物以及碳酸酐酶抑制剂的联合应用。未来用于治疗OSA的药物，无论是单一疗法还是与其他治疗方式联合使用，都将是个性化的，并基于可治疗的特征来解决潜在机制、合并症以及患者报告的结局指标。
